Media Coverage

Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.

Take a look at the latest Evaluate and Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us.

Jennifer Dinkel, Evaluate
Media & general questions
     

Latest Media Coverage

Nature Reviews Drug Discovery

FDA new drug approvals in Q1 2020

  In a quarter that was marked by the rapid spread of the COVID-19 pandemic, drug approvals continued (Table 1), but launching was a completely different…

Nature Reviews Drug Discovery

Top companies and drugs by sales in 2019

Roche is back on top. Over the past few years, the tussle for biopharma’s biggest company by sales has largely been contested by Novartis and Pfizer; but a winning streak…

Browse the archive

Handelsblatt

The stock market is discovering gene therapy

"Technologies such as Crispr are highly valued," says a study by the British analysis company EvaluatePharma, "but they also represent a high risk. Any serious setback…

Neue Zürcher Zeitung

The polycultis of the knee are in enviable form

According to estimates by market research firm Evaluate Pharma, the annual increase in prescription drug sales between 2019 and 2024 will reach almost 7% worldwide.

Fianze und Wirtschaft

Highly competitive market for cancer drugs

According to an estimate by data service provider EvaluatePharma, about $ 182 billion will be spent on research and development this year, much of it to fight more than…

Nature Reviews Drug Discovery

FDA new drug approvals in Q3 2019

The biggest approval of the third quarter was not a new drug, but an oral version of Novo Nordisk’s semaglutide, branded Rybelsus, which has a consensus sales forecast of…